C Diff. Prevention Candidate Heads Into Clinic With Ambitious Timetable
This article was originally published in The Pink Sheet Daily
Executive Summary
Synthetic Biologics thinks it can produce first product to prevent C. difficile infections by protecting microbiome from impact of I.V. beta lactam antibiotics; biotech plans IND in next two months and hopes to produce proof-of-concept data within roughly one year.